Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | Favezelimab and Pembrolizumab - (KEYFORM-007) | PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC) | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) vs Ipilimumab - (KEYNOTE-006) | Advanced Melanoma | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | GARDASIL9 (V503-064 ) | Human Papillomavirus (HPV) vaccine | Phase 3 | Data Released | Intramuscular | Immunology |
| Merck & Company Inc. | KEYTRUDA plus LENVIMA with TACE - (LEAP-012) | Unresectable, non-metastatic hepatocellular carcinoma | Phase 3 | Data Released | Intravenous and oral | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) with SBRT Therapy - (KEYNOTE-867 | Stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (KEYNOTE-630 | High-risk locally advanced cutaneous squamous cell carcinoma (cSCC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Merck & Company Inc. | Vibostolimab and Pembrolizumab - (KeyVibe-008) | Extensive-Stage Small Cell Lung Cancer | Phase 3 | Trial Discontinued | Intravenous infusion | Oncology |
| Merck & Company Inc. | Opevesostat (MK-5684/ODM-208) | Metastatic castration-resistant prostate cancer | Phase 3 | Ongoing | oral | Oncology |
